BACKGROUND: Metabolic imaging is of interest in esophageal cancer; however, the usefulness of initial standardized uptake value (SUV) in positron emission tomography (PET) is unknown in patients with esophageal or gastroesophageal carcinoma treated with definitive chemoradiotherapy. The authors hypothesized that initial SUV would correlate with patient outcome. METHODS: The authors retrospectively analyzed esophageal or gastroesophageal carcinoma patients who had baseline PET and endoscopic ultrasonography in addition to other routine staging. All patients received definitive chemoradiotherapy. Multiple statistical methods were used. RESULTS: The authors analyzed 209 consecutive esophageal or gastroesophageal carcinoma patients treated with definitive chemoradiation for outcome; of these, 180 had baseline PET for additional analyses. The median overall survival (OS) for all patients was 20.7 months (95% confidence interval, 18.8-26.3). Patients with clinical complete response (CR) lived longer than those with less than clinical CR (P < .0001). The median initial SUV was 12.7 (range, 0-51). Higher initial SUV was associated with longer tumors (P = .0001), higher T-stage status (P < .0001), positive N-stage status (P = .0001), higher overall stage (P < .0001), lack of clinical CR (P = .0002), and squamous cell histology (P < .0001). In the univariate analysis, initial SUV was associated with OS (Cox model, P = .016; log-rank test, P = .002). In the multivariate analysis, initial SUV dichotomized by the median value (P = .024) and tumor grade (P = .016) proved to be independent OS prognosticators. Median initial SUV for clinical CR patients was 10.2, compared with 15.3 for less than clinical CR patients (P = .0058). CONCLUSIONS: The data indicate that a higher initial SUV is associated with poorer OS in patients with esophageal or gastroesophageal carcinoma receiving definitive chemoradiation. Upon validation, baseline PET may become a useful stratification factor in randomized trials and for individualizing therapy.
BACKGROUND: Metabolic imaging is of interest in esophageal cancer; however, the usefulness of initial standardized uptake value (SUV) in positron emission tomography (PET) is unknown in patients with esophageal or gastroesophageal carcinoma treated with definitive chemoradiotherapy. The authors hypothesized that initial SUV would correlate with patient outcome. METHODS: The authors retrospectively analyzed esophageal or gastroesophageal carcinomapatients who had baseline PET and endoscopic ultrasonography in addition to other routine staging. All patients received definitive chemoradiotherapy. Multiple statistical methods were used. RESULTS: The authors analyzed 209 consecutive esophageal or gastroesophageal carcinomapatients treated with definitive chemoradiation for outcome; of these, 180 had baseline PET for additional analyses. The median overall survival (OS) for all patients was 20.7 months (95% confidence interval, 18.8-26.3). Patients with clinical complete response (CR) lived longer than those with less than clinical CR (P < .0001). The median initial SUV was 12.7 (range, 0-51). Higher initial SUV was associated with longer tumors (P = .0001), higher T-stage status (P < .0001), positive N-stage status (P = .0001), higher overall stage (P < .0001), lack of clinical CR (P = .0002), and squamous cell histology (P < .0001). In the univariate analysis, initial SUV was associated with OS (Cox model, P = .016; log-rank test, P = .002). In the multivariate analysis, initial SUV dichotomized by the median value (P = .024) and tumor grade (P = .016) proved to be independent OS prognosticators. Median initial SUV for clinical CRpatients was 10.2, compared with 15.3 for less than clinical CRpatients (P = .0058). CONCLUSIONS: The data indicate that a higher initial SUV is associated with poorer OS in patients with esophageal or gastroesophageal carcinoma receiving definitive chemoradiation. Upon validation, baseline PET may become a useful stratification factor in randomized trials and for individualizing therapy.
Authors: Xifeng Wu; Jian Gu; Tsung-Teh Wu; Stephen G Swisher; Zhongxin Liao; Arlene M Correa; Jun Liu; Carol J Etzel; Christopher I Amos; Maosheng Huang; Silvia S Chiang; Luke Milas; Walter N Hittelman; Jaffer A Ajani Journal: J Clin Oncol Date: 2006-06-19 Impact factor: 44.544
Authors: Arta Monir Monjazeb; Greg Riedlinger; Mebea Aklilu; Kim R Geisinger; Girish Mishra; Scott Isom; Paige Clark; Edward A Levine; A William Blackstock Journal: J Clin Oncol Date: 2010-09-27 Impact factor: 44.544
Authors: Srikrishna V Patnana; Santosh B Murthy; Lianchun Xiao; Eric Rohren; Wayne L Hofstetter; Stephen G Swisher; Zhongxing Liao; Jeffrey H Lee; Manoop S Bhutani; Homer A Macapinlac; Xuemei Wang; Jaffer A Ajani Journal: Cancer Date: 2010-10-01 Impact factor: 6.860
Authors: U Haberkorn; S I Ziegler; F Oberdorfer; H Trojan; D Haag; P Peschke; M R Berger; A Altmann; G van Kaick Journal: Nucl Med Biol Date: 1994-08 Impact factor: 2.408
Authors: Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg Journal: Clin Positron Imaging Date: 1999-05
Authors: L M Brown; C A Swanson; G Gridley; G M Swanson; J B Schoenberg; R S Greenberg; D T Silverman; L M Pottern; R B Hayes; A G Schwartz Journal: J Natl Cancer Inst Date: 1995-01-18 Impact factor: 13.506
Authors: Heta Javeri; Lianchun Xiao; Eric Rohren; Ritsuko Komaki; Wayne Hofstetter; Jeffrey H Lee; Dipen Maru; Manoop S Bhutani; Stephen G Swisher; Xuemei Wang; Jaffer A Ajani Journal: Cancer Date: 2009-02-01 Impact factor: 6.860
Authors: Geoffrey Y Ku; Anuja Kriplani; Yelena Y Janjigian; David P Kelsen; Valerie W Rusch; Manjit Bains; Joanne Chou; Marinela Capanu; Abraham J Wu; Karyn A Goodman; David H Ilson Journal: Cancer Date: 2016-05-06 Impact factor: 6.860
Authors: N K S Cheedella; A Suzuki; L Xiao; W L Hofstetter; D M Maru; T Taketa; K Sudo; M A Blum; S H Lin; J Welch; J H Lee; M S Bhutani; D C Rice; A A Vaporciyan; S G Swisher; J A Ajani Journal: Ann Oncol Date: 2012-12-17 Impact factor: 32.976
Authors: Elena Elimova; Xuemei Wang; Elba Etchebehere; Hironori Shiozaki; Yusuke Shimodaira; Roopma Wadhwa; Venkatram Planjery; Nikolaos Charalampakis; Mariela A Blum; Wayne Hofstetter; Jeff H Lee; Brian R Weston; Manoop S Bhutani; Jane E Rogers; Dipen Maru; Heath D Skinner; Homer A Macapinlac; Jaffer A Ajani Journal: Eur J Cancer Date: 2015-08-28 Impact factor: 9.162
Authors: Takashi Taketa; Arlene M Correa; Akihiro Suzuki; Mariela A Blum; Pamela Chien; Jeffrey H Lee; James Welsh; Steven H Lin; Dipen M Maru; Jeremy J Erasmus; Manoop S Bhutani; Brian Weston; David C Rice; Ara A Vaporciyan; Wayne L Hofstetter; Stephen G Swisher; Jaffer A Ajani Journal: Oncology Date: 2012-09-04 Impact factor: 2.935